Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?

Van Baelen, Karen; Desmedt, Christine; Wildiers, Hans; Neven, Patrick

Van Baelen, Karen; Desmedt, Christine; Wildiers, Hans; Neven, Patrick.

Afiliación

Van Baelen K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium.
Desmedt C; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium.
Wildiers H; Department of General Medical Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
Neven P; Department of Gynecological Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.

Ann Transl Med ; 11(6): 269, 2023 Mar 31.

Article en En | MEDLINE | ID: mdl-37082695

Palabras clave

Antibody-drug conjugates (ADCs); CDK4/6 inhibition resistance; metastatic breast cancer; oestrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer (ER+/HER2− breast cancer)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Transl Med Año: 2023 Tipo del documento: Article País de afiliación: Bélgica

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google